This technology uses specially designed sulfonium lipid nanoparticles to deliver mRNA directly to lung cells through the nose, offering a non-invasive, more effective and targeted treatment for pulmonary diseases like asthma and cystic fibrosis.
The field of pulmonary medicine faces significant challenges in the treatment of diseases such as cystic fibrosis, asthma, and acute respiratory distress syndrome, all of which involve complex interactions between lung epithelial and immune cells. Advances in genetic medicine, particularly messenger RNA (mRNA) therapeutics, have opened new avenues for treating these conditions by enabling the direct modulation of gene expression within target cells. However, the success of mRNA-based therapies hinges on the ability to deliver these fragile molecules efficiently and specifically to the relevant lung cells. Intranasal administration is a promising route due to its non-invasiveness and direct access to the respiratory tract, but it requires delivery systems that can protect mRNA from degradation and ensure its uptake by the desired cell types. Current approaches to mRNA delivery, such as conventional lipid nanoparticles, face several limitations when applied to pulmonary diseases. These formulations often lack the specificity needed to target lung epithelial and immune cells, resulting in suboptimal therapeutic outcomes and potential off-target effects. Furthermore, many existing nanoparticles struggle to traverse the mucus barrier and are rapidly cleared from the respiratory tract, reducing the amount of mRNA that reaches the intended cells. Inefficient encapsulation and delivery can also lead to degradation of the mRNA payload before it exerts its therapeutic effect. As a result, there is a pressing need for more effective and targeted delivery vehicles that can overcome these biological barriers and improve the efficacy of mRNA-based treatments for lung diseases.
This technology introduces a new class of sulfonium lipid nanoparticles specifically engineered for the intranasal delivery of mRNA molecules to lung epithelial and immune cells. These nanoparticles are carefully designed and synthesized to encapsulate and protect mRNA, ensuring efficient transport and localized release within the lungs. By optimizing the formulation, the technology achieves superior performance compared to existing lipid-based delivery systems, providing enhanced targeting and uptake by the intended lung cell populations. The system is designed to address the longstanding challenge of delivering genetic material directly to the respiratory tract, which is crucial for treating pulmonary diseases such as cystic fibrosis, asthma, and acute respiratory distress syndrome. What differentiates this technology is its unique chemical structure and formulation, which enable highly specific and efficient delivery of mRNA to lung cells via the intranasal route. Unlike conventional lipid nanoparticles, the sulfonium-based design offers improved stability, cellular uptake, and targeting capabilities, resulting in higher therapeutic efficacy and reduced off-target effects. The technology fills a critical gap in the market by providing a non-invasive, localized delivery method that can be readily adapted for a variety of mRNA-based therapeutics. Its development, supported by NIH funding and validated through rigorous experimentation and peer-reviewed disclosure, positions it as a leading solution for advancing pulmonary drug delivery and gene therapy.
• Enables targeted and efficient intranasal delivery of mRNA to lung epithelial and immune cells
• Optimized sulfonium lipid nanoparticles outperform existing benchmark lipid formulations for mRNA delivery
• Facilitates localized gene expression critical for treating pulmonary diseases such as cystic fibrosis, asthma, and acute respiratory distress syndrome
• Non-invasive administration route through intranasal delivery improves patient compliance
• Supports development of novel mRNA-based therapeutics for a wide range of lung diseases
• Innovative chemical design avoids reliance on existing intellectual property, allowing for broad application and further development
• mRNA therapeutics for cystic fibrosis
• Asthma gene therapy delivery
• Acute respiratory distress treatment
• Targeted lung cancer mRNA therapy
• Vaccines for respiratory infections
Patent application: 63/783,376, filed on 4/4/2025
Issued patent
Know-how based
Copyright
TRL 3
Sulfonium lipid nanoparticles are specifically engineered for the intranasal delivery of mRNA molecules to lung epithelial and immune cells
This technology is available for licensing.